Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial
Michael B. Atkins(Georgetown Lombardi Comprehensive Cancer Center), Elizabeth R. Plimack(Fox Chase Cancer Center), Igor Puzanov(Vanderbilt University Medical Center), Mayer Fishman(Moffitt Cancer Center), David F. McDermott(Beth Israel Deaconess Medical Center), Daniel C. Cho(NYU Langone Health), Ulka N. Vaishampayan(The Barbara Ann Karmanos Cancer Institute), Saby George(Roswell Park Comprehensive Cancer Center), Thomas Olencki(The Ohio State University Wexner Medical Center), Jamal Tarazi(Pfizer (United States)), Brad Rosbrook(Pfizer (United States)), Kathrine C. Fernandez(Pfizer (United States)), Mariajosé Lechuga(Pfizer (Italy)), Toni K. Choueiri(Dana-Farber Cancer Institute)
Cited by 367
Abstract
Related Papers
No related papers found
Powered by citation graph analysis